LAHORE GENERAL HOSPITAL LAHORE

RESULT OF GRIEVANCE COMMITTEE MEETING HELD ON 25-11-2020 TO ADDRESS THE GRIEVANCE IN BULK PURCHASE OF MEDICINES FOR THE YEAR 2020-2021

S.No	Grievance submitted by	Description	Decision By Grievance Committee
1.	M/s Friends Pharma (Pvt) diary No. 11472/LGH, Dated 10-11-2020. The firm submitted its grievance against the non responsiveness of their product T.E No.223 Tab/ Cap Omeprazole 20mg. firm claims that their Raw Material of their product (Omeprazole) is WHO & FDA approved. The firm is requesting to qualify their product.	Firm experience is not as per requirement and the submitted documents are insufficient. Hence the firm stood disqualify.	Grievance committee discussed the matter in detail and after hearing the M/s Friends Pharma (Pvt) view point on the matter unanimously decided to **turn down the grievance** as the firm could not justify their grievance. **So the submitted grievance rejected.**
2.	M/s Schazoo Pharmaceuticals (Pvt) Ltd. submitted its grievance bearing diary No. 11494/LGH, Dated 10-11-2020 against the non responsiveness of their product T.E No.201 Tab. Naproxen Sodium 550mg. The firm is requesting to allow them to appear before the Grievance committee to clarify about the issues of specifications of their product.	The specification of the Tab. Naproxen Sodium 550mg is found as per specification of bidding documents 2020-21.	The grievance committee accepted the grievance and T.E No.201 Tab. Naproxen Sodium 550mg is responsive.
3.	M/s Mukhtar Enterprises submitted its grievance bearing diary No. 11433/LGH, Dated 09-11-2020 against the non responsiveness of their product T.E No.52 & 53 (Colistimethate Sodium 1MIU&2MIU). The firm claims that their product Colistimethate sodium mfg. by Xellia Pharmceuticals ApS Denmark is the only product available in Pakistan which is FDA approved in finish dosage form and also have bio equivalent study.	M/s Mukhtar Enterprises quoted water for injection of other firm (FDL). While as per bidding document WFI should be from the same manufacturer.	Grievance committee discussed the matter in detail and after hearing the M/s Mukhtar Enterprises view point on the matter unanimously decided to take opinion from end user. **So the submitted grievance T.E No. 52** (Colistimethate Sodium 1MIU) **is rejected and T.E No. 53** (Colistimethate Sodium 2MIU) **is accepted.**

4.	M/s Abbott Laboratories (Pakistan) Ltd. submitted its grievance bearing diary No. 11549/LGH, Dated 11-11-2020 against the non responsiveness of their product(s) 1. **T.E No.201 Flexin 500mg.** The firm is stating that their product which contains naproxen is being used in various public sectors and so the efficacy and safety is well tried and time tested. 2. **T.E 177 Epival 500mg.** The firm is requesting their product is original research brand of Abbott. The firm is requesting to consider their products.	**T.E No.201 Flexin 500mg** The specification of the Tab. Naproxen 550mg is not fulfilled by the firm according to the specifications of bidding documents 2020-21. 2. **T.E 177 Epival 500mg.** The other two firms M/s Platinum Pharmaceuticals & M/s Wimits Pharma responsive on the basis of specifications and as per bidding documents criteria.	Grievance committee discussed the matter in detail and after hearing the M/s Abbott Laboratories (Pakistan) Ltd. view point on the matter unanimously decided that **T.E No. 201 (**Flexin 500mg**)** and **T.E No. 177 (**Epival 500mg**) are accepted.** Hence M/s Platinum Pharmaceuticals (Pvt) Ltd. Pakistan and M/s Wimits Pharmaceuticals (Pvt) Ltd are **non responsive**.
5.	M/s Abbott Laboratories (Pakistan) Ltd. submitted its grievance bearing diary No. 11550/LGH, Dated 11-11-2020 against the non responsiveness of their product(s) 1.T.E. No. 21 (Acyclovir 500mg) 2.T.E. 51 Klaricid I.V 3.T.E 146 Vancomycin 500mg The firm is stating that their injectable Lyophilized products contain sterile water for injection manufactured by Surge Laboratories. They are requesting to consider their products alongwith water for injection mfg. by Surge Lab.	The firm quoted water for injection of other firm (Surge). While as per bidding document WFI should be from the same manufacturer.	Grievance committee discussed the matter in detail and after hearing the M/s Abbott Laboratories (Pakistan) Ltd. view point on the matter unanimously decided to accept the grievance for **T.E No. 51 and T.E No. 21.** While the grievance of **TE. No. 146 (**Vancomycin 500mg**)** is **pending**.
6.	M/s Hakimsons (impex) Pvt. Ltd. submitted its grievance bearing diary No. 11589/LGH, Dated 12-11-2020 against the non responsiveness of their product T.E No. 28 (Rhophylac injection). Firm is requesting to approve their item as their item is US-FDA approved.	Bioequivalence / Biosimilarity is not required for Plasma derived products according to WHO. The condition may be relaxed for the availability of life saving products in the hospital.	Grievance committee discussed the matter in detail and after hearing the M/s Hakimsons (impex) Pvt. Ltd. view point on the matter unanimously decided to **accept** the grievance.

7.	M/s Martin Dow Ltd. submitted its grievance bearing diary No. 11555/LGH, Dated 11-11-2020 against the non responsiveness of their product T.E No. 201 Tab. Naproxen Sodium. The firm is requesting to consider their product as responsive.	Samples are not as per specifications of tender list / bidding documents.	Grievance committee discussed the matter in detail and after hearing the M/s Martin Dow Ltd. view point on the matter unanimously decided to **accept** the grievance.
8.	M/s The Eastern Trade & Distribution Co Pvt. Ltd. submitted its grievance bearing diary No. 11569/LGH, Dated 12-11-2020 against the non responsiveness of their product(s) 1.T.E No.80 Inj. Human Albumin 2.TE118 IgM (Pentaglobin 0.50gm) 3.T.E 119IgM (Pentaglobin 5.0gm) The firm is stating that bioequivalence studies are not necessary for parenteral administered drugs and are exempted from bioequivalence study requirements. The firm is requesting to consider their products.	Bioequivalence / Biosimilarity are not required for Plasma derived products according to WHO. The condition may be relaxed for the availability of life saving products in the hospital.	Grievance committee discussed the matter in detail and after hearing the M/s The Eastern Trade & Distribution Co Pvt. Ltd. view point on the matter unanimously decided to **accept** the grievance.
9.	M/s Amson Vaccines & Pharma Pvt. Ltd. submitted its grievance bearing diary No. 11579/LGH, Dated 12-11-2020 against the non responsiveness of their product(s) T.E 31 Imatet and 30 ASVS Injections. The firm is stating the bioequivalence studies are not required for injectable as per European Medicine Agency's Guidline on the Investigation of Bioequivalence (study enclosed). The firm is requesting to consider their products as responsive.	Bioequivalence / Biosimilarity is not required for Plasma derived products according to WHO. The condition may be relaxed for the availability of life saving products in the hospital.	Grievance committee discussed the matter in detail and after hearing the M/s Amson Vaccines & Pharma Pvt. Ltd. view point on the matter unanimously decided to **accept** the grievance and both the items are responsive.
10.	M/s Relizon Pharmaceuticals submitted its grievance bearing diary No. 11608/LGH, Dated 12-11-2020. Firm is requesting to re-evaluate the tender documents for the bulk purchase of medicines. Firm has attached documents i.e. API Trails, GMP of manufacturer, COA of API, Import Goods Declaration (GD's), Local Market experience etc.	All quoted items are non responsive due to short experience as per requirement/ bidding documents.	Grievance committee discussed the matter in detail and after hearing the M/s Relizon Pharmaceuticals view point on the matter unanimously decided to turn down the grievance, so the grievance is **rejected**.

11.	M/s AA Pharma submitted its grievance bearing diary No. 11609/LGH, Dated 12-11-2020 against the non responsiveness of their product(s) T.E 70 Inj. Erythropoietin EPIAO 4000 IU PFS. Firm is stating that their product is Bioequivalence and Bio Similarity. Firm is requesting to consider their product.	Bio equivalent study / bio similar study submitted by the firm is not as per requirement.	Grievance committee discussed the matter in detail and after hearing the M/s AA Pharma view point on the matter unanimously decided to turn down the grievance, so the grievance is **rejected**.
12.	M/s Getz Pharma submitted its grievance bearing diary No. 11636/LGH, Dated 13-11-2020 against the non responsiveness of their product(s) T.E 48 Inj. Ceftriaxone 1gm. The firm is stating that their source of ceftriaxone raw material from FDA approved plant. Firm is requesting to consider their product.	The firm has submitted the required documents and may be responsive.	Grievance committee discussed the matter in detail and after hearing the M/s Getz Pharma view point on the matter unanimously decided to **accept** the grievance and item TE No.48 responsive.
13.	M/s Titlis Pharma submitted its grievance bearing diary No. 11637/LGH, Dated 13-11-2020 against the non responsiveness of their product(s) T.E 70 Erythropoietin 4000IU PFS. Firm has submitted Bioequivalence study and requesting to consider their product.	Bio equivalent study / bio similar study submitted by the firm is not as per requirement.	Grievance committee discussed the matter in detail and after hearing the M/s Titlis Pharma view point on the matter unanimously decided to turn down the grievance, so the grievance is **rejected**.
14.	M/s Getz Pharma submitted its grievance bearing diary No. 11637/LGH, Dated 13-11-2020 against the non responsiveness of their product(s) T.E 86, 87 & 88 Inj. Insulins. Firm stated that their product insuget is a technology transferred product from Biocon Ltd India and therefore development and clinical studies were conducted by Biocon Ltd before product transferred to Getz Pharma. The firm submitted API FDA bioequivalence / Biosimilar study and and Thermo Loger data sheet along with this letter. The firm is requesting to consider their firm to qualify for this product.	Bio equivalent study / bio similar study submitted by the firm is not as per requirement.	Grievance committee discussed the matter in detail and after hearing the M/s Getz Pharma view point on the matter unanimously decided to **accept** the grievance and their product(s) T.E 86, 87 & 88 Inj. Insulins are responsive

15.	M/s Atco Laboratories submitted its grievance bearing diary No. 11643/LGH, Dated 13-11-2020 for correction of mfg. name which was printed as Atco Pharmaceuticals rather than Atco Laboratories on the evaluation report against the T.E Nos. 264, 268, 269, 270 & 270. Firm is requesting for the amendment of name.	Typographic error has been removed.	Grievance committee discussed the matter in detail and after hearing the M/s Atco Laboratories view point on the matter unanimously decided to **accept** the grievance.
16.	M/s Nabi Qasim Industries submitted its grievance bearing diary No. 11584/LGH, Dated 12-11-2020 against the non responsiveness of their product(s) T.E No. 146 Inj. Vancomycin 500mg. Firm is stating that their product has been non responsive due to WFI should be from same manufacturer. Firm attached a letter by Ministry of Health, Pakistan regarding relaxation for water for injection of the same manufacturer. Firm claims that according to attached letter registration board has not restricted / imposed condition for provision of diluents manufactured by same manufacturer. The firm is requesting to consider their product for health competition.	The firm quoted water for injection of other firm. While as per bidding document WFI should be from the same manufacturer.	**T.E No. 146 (**Vancomycin 500mg**)** the case is **pending**.
17.	M/s PharmaWise Lab. submitted its grievance bearing diary No. 11647/LGH, Dated 13-11-2020 against the non responsiveness of their product(s) T.E 283 Surgical Scrub Povidone Iodine 450ml. The firm stated that their item has been technically disqualified due to reason of less sale record. Now the firm has attached the sale record of the said items. Firm is requesting to consider their product.	Submitted record do not fulfill the requirement i.e experience is less as per requirement.	Grievance committee discussed the matter in detail and after hearing the M/s Pharma Wise Lab. view point on the matter unanimously decided to turn down the grievance, so the grievance is **rejected.**
18.	M/s Glitz Pharma submitted its grievance bearing diary No. 11648/LGH, Dated 13-11-2020 against the non responsiveness of their item(s) T.E No.174 & 175 Tab. Deferasirox 250mg & 500mg. the firm submitted some required documents relating to these items and requesting to consider their products as responsive.	After re-evaluation of the bid, the experience is not as per requirement of the bidding documents.	Grievance committee discussed the matter in detail and after hearing the M/s Glitz Pharma view point on the matter unanimously decided to turn down the grievance, so the grievance is **rejected.**

19.	M/s Wimits Pharmaceuticals submitted its grievance bearing diary No. 11649/LGH, Dated 13-11-2020 against the non responsiveness of their item(s) T.E No.143 Tramadol Inj. T.E No.219 Doxycycline cap. Firm stated that their items declared non responsive due to some documents missing. Firm has attached some documents and requesting to consider their products as responsive.	The firm submitted documents alongwith Grievance, hence their item T.E No.143 Tamadol Inj. may be responsive while T.E No.219 Doxycycline remains non responsive as per documents.	Grievance committee discussed the matter in detail and after hearing the M/s Wimits Pharmaceuticals view point on the matter unanimously decided to take opinion from end user. So the submitted grievance **T.E No. 219** (Doxycycline cap.) is **rejected** and **T.E No. 143** (Tramadol Inj.) is **accepted.**
20.	M/s Wilshire submitted its grievance bearing diary No. 11652/LGH, Dated 13-11-2020 against the non responsiveness of their item(s) T.E No. 14 Inf. Linezolid T.E No. 16 Inf. Moxifloxacin T.E No. 146 Inj. Vancomycin Firm claims that their products are non responsive as they had attached all the required documents along with their bid. Firm is requesting to consider their products as responsive.	Items may be responsive on the basis of documents provided along with grievance.	Grievance committee discussed the matter in detail and after hearing the M/s Wilshire view point on the matter unanimously decided that **T.E No. 14** and **T.E No. 16** are **accepted.** While the case **T.E No. 146 (**Vancomycin 500mg**)** is **pending**.
21.	M/s Novartis Pharma submitted its grievance bearing diary No. 11674/LGH, Dated 14-11-2020 against the non responsiveness of their item(s) T.E No. 170 Tab. Cyclosporine. Firm is stating that their quoted product is their original research based product and the API source is MPRA approved, European standard.	Firm was non responsive due to the product in Tab. form instead of capsule.	Grievance committee discussed the matter in detail and after hearing the M/s Novartis Pharma view point on the matter unanimously decided to **accept** the grievance and T.E No. 170 Tab. Cyclosporine is hereby responsive.
22.	M/s Genome Pharmaceuticals submitted its grievance bearing diary No. 11675/LGH, Dated 14-11-2020 against the responsiveness of their competitor's products TE 174 & 175 Tab. Deferasirox 250mg & 500mg respectively. Firm is requesting to disqualify their competitor's products due to non experience in government/ thalassemia centers and the product is packed in bottle form which is hindrance in dispensing in lose form.	02 firms out of 06 responsive for these products TE No. 174 & 175 Tab. Deferasirox 250mg & 500mg respectively.	Grievance committee discussed the matter in detail and after hearing the M/s Genome Pharmaceuticals view point on the matter unanimously decided to **accept** the grievance hence M/s AJ Mirza Pharma (Pvt) Ltd. is **non responsive** for TE No. 174 & 175 Tab. Deferasirox 250mg & 500mg.

23.	M/s Sami Pharmaceuticals submitted its grievance bearing diary No. 11689/LGH, Dated 14-11-2020 against the non responsiveness of their item(s) T.E No. 70 Erythropoietin 4000 IU. Firm has attached a copy of Source of API, Thermalog data sheet of the quoted product and Biosimilar study along with the grievance and requesting to consider their product as responsive.	Bio equivalent study / bio similar study submitted by the firm is not as per requirement.	Grievance committee discussed the matter in detail and after hearing the M/s Sami Pharmaceuticals view point on the matter unanimously decided to **accept** the grievance and T.E No. 70 Erythropoietin 4000 IU is responsive.
24.	M/s Next Pharmaceutical submitted its grievance bearing diary No. 11690/LGH, Dated 14-11-2020 against the non responsiveness of their item(s) T.E No.196 (Tab. Montelukast), T.E No.209 (Tab. Sitagliptin + Merformin), T.E 224 Cap. Pregabalin). Firm stated that their products declared non responsive due to expired GMP and APIs certificates. Now the firm has attached valid certificates of GMP and API and requesting to consider their products.	TE 196 & 224 may be responsive as the firm has submitted required documents along with the grievance, while T.E No. 209 documents do not support to qualify.	Grievance committee discussed the matter in detail and after hearing the M/s Next Pharmaceutical view point on the matter unanimously decided that **T.E No. 196 and T.E No. 224** are **accepted.** While the grievance **T.E No. 209** (Tab. Sitagliptin + Merformin) **is rejected**.
25.	M/s Hilton Pharma submitted its grievance bearing diary No. 11691/LGH, Dated 14-11-2020 against the non responsiveness of their item(s) T.E No. 144 Inj. Tranexamic Acid. The firm stating that their product has been non responsive due to reason of API Source not attached with the bid. The firm stating that they have attached the API source and requesting to consider their product as responsive.	Submitted documents are not according to the specifications.	Grievance committee discussed the matter in detail and after hearing the M/s Hilton Pharma view point on the matter unanimously decided to turn down the grievance, so the **grievance is rejected.**
26.	M/s Unisa Pvt Ltd. submitted its grievance bearing diary No. 11697/LGH, Dated 14-11-2020 against the non responsiveness of their item(s) T.E No. 284 Disposable infusion set Y-Port. Firm stated that their product has been non responsive due to less amount of CDR attached. Firm stated that the annual qty of this product was mistakenly written as 10000000 instead of 1000000 which was corrected vide corrigendum. The firm is requesting to accept their grievance and consider their product.	Sample rejected by the End User.	The case for **T.E No. 284** (I.V set) is **Pending.**

27.	M/s Adcare Pharma submitted its grievance bearing diary No. 11699/LGH, Dated 14-11-2020 against the non responsiveness of their item(s) T.E No 254 Inhalation Isoflurane. The firm claims that their competitor has been qualified in the technical evaluation inspite of the following deficiencies i.e Restane was recalled by the provincial Drug Controller, Isoflorane as a sedating agent used in operating rooms where a minor reaction of product can lead to life threatening condition. The firm is requesting keeping in view of stated deficiencies in the competitor's brand, to qualify their product.	Firm was non responsive due to lack of ISO certificate. Now the Firm has submitted ISO certificate.	Grievance committee discussed the matter in detail and after hearing the M/s Adcare Pharma view point on the matter unanimously decided to **accept** the grievance **and TE No.** 254 Inhalation Isoflurane responsive.
28.	M/s Martin Dow submitted its grievance bearing diary No. 11700/LGH, Dated 14-11-2020 against the responsiveness of their competitor's item(s) T.E No. 108 Inj. Midazolam. Firm claims that their product is a quality based product with EUDRA GMP certified while their competitors product have not sufficient manufacturing quota of the said product to cater the need in different Govt. institutes. i.e 400000 annual quota while LGH annual demand is 150000.	Both the firms responsive for this product.	Case is Pending by the Grievance Committee.
29.	M/s Brookes submitted its grievance bearing diary No. 11701/LGH, Dated 14-11-2020 against the responsiveness of their competitors item(s) T.E 282 Povidone Iodine solution. Firm stated that their competitors Glitz Pharma, Kohinoor & Pharmawise also participated in the same generic which are technically eligible without keeping the following deficiencies; Non availability of standard analytical reports, less past experience, not freely available in the market & the stated firms are not prequalified in any Govt. institutes. The firm is requesting to only qualify them.	The product of M/s Brookes Pharma and their competitors's products (Glitz Pharma, Kohinoor & Pharmawise) are responsive.	The case for **T.E No. 282** (Povidone Iodine solution) is **pending.**

30.	M/s 3H Hoffmann Human Health submitted its grievance bearing diary No. 11702/LGH, Dated 14-11-2020 against the non responsiveness of their item(s) T.E No 170, 171 & 172 (Cyclosporine 100mg, 50&25mg). the firm stated that their products have been non responsive due to the product in tablet form instead of capsule. The firm claims that as per DRAP data all available brand of Cyclosporine are available in Capsules form. The firm is requesting to qualify their product.	Firm was non responsive due to the product in Tab. form instead of capsule.	Grievance committee discussed the matter in detail and after hearing the M/s 3H Hoffmann view point on the matter unanimously decided to **accept** the grievance **and** their item(s) T.E No 170, 171 & 172 (Cyclosporine 100mg, 50&25mg) are responsive.
31.	M/s Aster Life Sciences submitted its grievance bearing diary No. 11703/LGH, Dated 14-11-2020 against the non responsiveness of their item(s) T.E No 70 Erythropoietin 4000IU. The firm stated that their product is available in prefilled syringe, their product is carrying Biosimilar study (copy attached), they are maintaining thermolog data sheets from south korea (attached). Firm is requesting to consider their product as responsive.	Bio equivalent study / bio similar study submitted by the firm is not as per requirement.	Grievance committee discussed the matter in detail and after hearing the M/s Aster Life Sciences view point on the matter unanimously decided to turn down the grievance, so the grievance is **rejected.**
32.	M/s Hamaz Pharmaceuticals submitted its grievance bearing diary No. 11704/LGH, Dated 14-11-2020 against the non responsiveness of their item(s) T.E Nos. 17 Paracetamol Inj. 47 Ceftazidime Inj. 48 Ceftriaxone 62 Diclofenac sodium Inj. 166 Ciprofloxacin tab. 176 Diclofenac sodium Tab. 180 Escitalopram Tab. 186 Levofloxacin Tab. 196 Montelukast Tab. 203 Paracetamol Tab. 229 Ibuprofen susp. 237 Paracetamol Syrup 46 Cefotaxime Inj. 63 Dimenhydrinate inj. 165 Cetirizine Tab. 218 Cefixime Cap. 223 Omeprazole Cap. 228 Cefixime Suspension 234 Cetirizine Dihydrochloride 238 Zinc Sulphate syrup Firm is requesting that their products have been disqualified due to non fulfilling the criteria of Past Performance whereas under the same criteria only one product has declared Qualified. Firm claims that their products have been declared qualified in different Government institutions. Firm is requesting to consider their products as responsive.	Due to typographic error one item of this firm was mistakenly responsive, which was amended. The firm is non responsive due to short experience of quoted items.	Grievance committee discussed the matter in detail and after hearing the M/s Hamaz Pharmaceuticals view point on the matter unanimously decided to turn down the grievance, so all the quoted items are hereby **rejected.**

33.	M/s Atlantic Pharmaceuticals submitted its grievance bearing diary No. 11705/LGH, Dated 14-11-2020 against the non responsiveness of their item(s) T.E No. 29 Inj. Anti Rabies Vaccine. Firm is stating that the API & Thermalog data sheet is already attached in their bid and they are providing bioequivalence study report vide this grievance. Firm is requesting to consider their product as responsive.	Bioequivalence / Biosimilarity is not required for Plasma derived products according to WHO. The condition may be relaxed for the availability of life saving products in the hospital.	Grievance committee discussed the matter in detail and after hearing the M/s Atlantic Pharmaceuticals view point on the matter unanimously decided to **accept** the grievance **and** their item(s) T.E No. 29 Inj. Anti Rabies Vaccine is responsive.
34.	M/s Effort Pharmaceuticals Pvt. Ltd. submitted its grievance bearing diary No. 11683/LGH, Dated 14-11-2020 against the non responsiveness of their item(s) T.E Nos. 166 Tab. Ciprofloxacin500mg & 223 Cap. Omeprazole 20mg due to the shortage of some documents. The firm has submitted some documents and requested to consider their products.	Items are non responsive due to short experience of the quoted items.	Grievance committee discussed the matter in detail and after hearing the M/s Effort Pharmaceuticals Pvt. Ltd. view point on the matter unanimously decided to turn down the grievance, so the grievance is **rejected.**
35.	M/s Roche Pakistan Ltd submitted its grievance bearing diary No. 11687/LGH, Dated 14-11-2020 against the non responsiveness of their item(s) T.E Nos. 70 Erythropoietin 4000 IU.	Hospital demanded Inj. Erythropoietin 4000 IU. While the firm quoted Erythropoietin 5000 IU which is not as per specification.	Grievance committee discussed the matter in detail and after hearing the M/s Roche Pakistan Ltd view point on the matter unanimously decided to turn down the grievance, so the grievance is **rejected.**
36.	M/s Stallion Pharmaceuticals Pvt. Ltd. submitted its grievance bearing diary No. 11688/LGH, Dated 14-11-2020 against the non responsiveness of their item(s) T.E Nos. 25 (Inj. Amoxycillin 1000+Clavulanic acid 200mg) 101 (Inj. Meropenem) 124 & 125 (Inj. Piperacillin+Tazobactam) due to non providing of water for injection of same manufacturer. & T.E 83 Inj. Imepenem+Cilastatin. Firm is requesting to reconsider their firm for the above products.	The firm quoted water for injection of other firm. While as per bidding document WFI should be from the same manufacturer.	Grievance committee discussed the matter in detail and after hearing the M/s Stallion Pharmaceuticals Pvt. Ltd. view point on the matter unanimously decided to **accept** the grievance and the mentioned items are responsive**.**

37.	M/s MTI Medical Pvt. Ltd. submitted its grievance bearing diary No. 11693/LGH, Dated 14-11-2020 against the non responsiveness of their item(s) T.E No. 21 (Inj. Acyclovir 500mg) 52 (Inj. Colistimethate Sodium) 137 (Inj. Tigecycline) Firm stated that their products have been non responsive due to following reasons; 1. Source of API should FDA/WHO/EMA approved. 2. Product and WFI should be from same mfg. For first point the firm states that their products API sources are FDA approved. They have attached the related documents. For the second point the firm claims that mostly firms including brands have no house facility to manufacture WFI in the same plant. The firm is requesting to consider their products.	The firm quoted water for injection of other firm. While as per bidding document WFI should be from the same manufacturer. While documents relating to API sources and FDA did not attach along with Technical offer and with the grievance.	Grievance committee discussed the matter in detail and after hearing the M/s MTI Medical Pvt. Ltd. view point on the matter unanimously decided to **turn down the grievance** as the firm could not justify their grievance for **T.E No 52** (Inj. Colistimethate Sodium) is **rejected** and **T.E No. 21**(Inj. Acyclovir 500mg) & **T.E No 137** (Inj. Tigecycline) are hereby **accepted**.
38.	M/s Popular International submitted its grievance bearing diary No. 11716/LGH, Dated 16-11-2020 against the non responsiveness of their item(s) T.E No.28 Inj. Anti D & 85 Inj. Immunoglobulins 5% Firm stated that their product has been non responsive due to non availability of bioequivalence study and Thermolog data sheet. Firm claims that their product is human plasma bases and neither biosimilar nor generic products this requirement is not applicable for their product. In this regard the firm attached a letter of non applicable bioequivalence study and thermolog data sheet and requesting to consider their product as responsive.	Bioequivalence / Biosimilarity is not required for Plasma derived products according to WHO. The condition may be relaxed for the availability of life saving products in the hospital.	Grievance committee discussed the matter in detail and after hearing the M/s Popular International view point on the matter unanimously decided to **accept** the grievance **for** item(s) T.E No.28 Inj. Anti D & 85 Inj. Immunoglobulins 5%.
39.	M/s ICI Pakistan Ltd. submitted its grievance bearing diary No. 11717/LGH, Dated 16-11-2020 against the non responsiveness of their item(s) T.E Nos. 46.(Cefotaxime 1gm with WFI) 47.(Ceftazidime 1gm with WFI) 48.(Ceftriaxone 1g with WFI) 82.(Hydrocortisone Inj. 250mg) 83.(Imipenem+Cilastin Inj. 500mg) 101.(Meropenem Inj. 1gm) 124.(Piperacillin+Tazobactam) 125.(Piperacillin+Tazobactam) The firm stated that their products have been non responsive due to WFI from other source. Firm stated that they have to arrange other source WFI	The firm quoted water for injection of other firm. While as per bidding document WFI should be from the same manufacturer.	Grievance committee discussed the matter in detail and after hearing the M/s ICI Pakistan Ltd. view point on the matter unanimously decided to accept the grievance hence all mentioned items are hereby responsive.

	(Surg Lab.) due to highly demand from public sectors. However, the firm is declaring that they will arrange to supply WFI manufactured by their own source, i.e. ICI Pakistan Limited but in case of extreme emergency they will supply WFI from other source. In this regard the firm is requesting to consider their products as responsive.		
40.	M/s MTI Medical (Pvt) Ltd. submitted its grievance bearing diary No. 11906/LGH against the non responsiveness of their item(s) T.E 128 Inj. Remdesivir. Firm is requesting to consider the product.		Grievance committee discussed the matter in detail and after hearing the M/s MTI Medical (Pvt) Ltd. view point on the matter unanimously decided to **accept** the grievance**.**